Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antimalarials
/ administration & dosage
Body Weight
Child
Child, Preschool
Drug Administration Schedule
Female
Humans
Infant
Malaria, Vivax
/ prevention & control
Male
Middle Aged
Plasmodium vivax
/ drug effects
Primaquine
/ administration & dosage
Young Adult
Age-based dosing
Allometric scaling
Plasmodium vivax
Primaquine
Weight-based dosing
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
09 Sep 2021
09 Sep 2021
Historique:
received:
30
03
2021
accepted:
18
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
17
11
2021
Statut:
epublish
Résumé
In many endemic areas, Plasmodium vivax malaria is predominantly a disease of young adults and children. International recommendations for radical cure recommend fixed target doses of 0.25 or 0.5 mg/kg/day of primaquine for 14 days in glucose-6-phosphate dehydrogenase normal patients of all ages. However, for many anti-malarial drugs, including primaquine, there is evidence that children have lower exposures than adults for the same weight-adjusted dose. The aim of the study was to develop 14-day weight-based and age-based primaquine regimens against high-frequency relapsing tropical P. vivax. The recommended adult target dose of 0.5 mg/kg/day (30 mg in a 60 kg patient) is highly efficacious against tropical P. vivax and was assumed to produce optimal drug exposure. Primaquine doses were calculated using allometric scaling to derive a weight-based primaquine regimen over a weight range from 5 to 100 kg. Growth curves were constructed from an anthropometric database of 53,467 individuals from the Greater Mekong Subregion (GMS) to define weight-for-age relationships. The median age associated with each weight was used to derive an age-based dosing regimen from the weight-based regimen. The proposed weight-based regimen has 5 dosing bands: (i) 5-7 kg, 5 mg, resulting in 0.71-1.0 mg/kg/day; (ii) 8-16 kg, 7.5 mg, 0.47-0.94 mg/kg/day; (iii) 17-40 kg, 15 mg, 0.38-0.88 mg/kg/day; (iv) 41-80 kg, 30 mg, 0.37-0.73 mg/kg/day; and (v) 81-100 kg, 45 mg, 0.45-0.56 mg/kg/day. The corresponding age-based regimen had 4 dosing bands: 6-11 months, 5 mg, 0.43-1.0 mg/kg/day; (ii) 1-5 years, 7.5 mg, 0.35-1.25 mg/kg/day; (iii) 6-14 years, 15 mg, 0.30-1.36 mg/kg/day; and (iv) ≥ 15 years, 30 mg, 0.35-1.07 mg/kg/day. The proposed weight-based regimen showed less variability around the primaquine dose within each dosing band compared to the age-based regimen and is preferred. Increased dose accuracy could be achieved by additional dosing bands for both regimens. The age-based regimen might not be applicable to regions outside the GMS, which must be based on local anthropometric data. Pharmacokinetic data in small children are needed urgently to inform the proposed regimens.
Sections du résumé
BACKGROUND
BACKGROUND
In many endemic areas, Plasmodium vivax malaria is predominantly a disease of young adults and children. International recommendations for radical cure recommend fixed target doses of 0.25 or 0.5 mg/kg/day of primaquine for 14 days in glucose-6-phosphate dehydrogenase normal patients of all ages. However, for many anti-malarial drugs, including primaquine, there is evidence that children have lower exposures than adults for the same weight-adjusted dose. The aim of the study was to develop 14-day weight-based and age-based primaquine regimens against high-frequency relapsing tropical P. vivax.
METHODS
METHODS
The recommended adult target dose of 0.5 mg/kg/day (30 mg in a 60 kg patient) is highly efficacious against tropical P. vivax and was assumed to produce optimal drug exposure. Primaquine doses were calculated using allometric scaling to derive a weight-based primaquine regimen over a weight range from 5 to 100 kg. Growth curves were constructed from an anthropometric database of 53,467 individuals from the Greater Mekong Subregion (GMS) to define weight-for-age relationships. The median age associated with each weight was used to derive an age-based dosing regimen from the weight-based regimen.
RESULTS
RESULTS
The proposed weight-based regimen has 5 dosing bands: (i) 5-7 kg, 5 mg, resulting in 0.71-1.0 mg/kg/day; (ii) 8-16 kg, 7.5 mg, 0.47-0.94 mg/kg/day; (iii) 17-40 kg, 15 mg, 0.38-0.88 mg/kg/day; (iv) 41-80 kg, 30 mg, 0.37-0.73 mg/kg/day; and (v) 81-100 kg, 45 mg, 0.45-0.56 mg/kg/day. The corresponding age-based regimen had 4 dosing bands: 6-11 months, 5 mg, 0.43-1.0 mg/kg/day; (ii) 1-5 years, 7.5 mg, 0.35-1.25 mg/kg/day; (iii) 6-14 years, 15 mg, 0.30-1.36 mg/kg/day; and (iv) ≥ 15 years, 30 mg, 0.35-1.07 mg/kg/day.
CONCLUSION
CONCLUSIONS
The proposed weight-based regimen showed less variability around the primaquine dose within each dosing band compared to the age-based regimen and is preferred. Increased dose accuracy could be achieved by additional dosing bands for both regimens. The age-based regimen might not be applicable to regions outside the GMS, which must be based on local anthropometric data. Pharmacokinetic data in small children are needed urgently to inform the proposed regimens.
Identifiants
pubmed: 34503519
doi: 10.1186/s12936-021-03886-w
pii: 10.1186/s12936-021-03886-w
pmc: PMC8427859
doi:
Substances chimiques
Antimalarials
0
Primaquine
MVR3634GX1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
366Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 210599/Z/18/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT-iTP-2018/001
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
Pharmaceutics. 2021 May 03;13(5):
pubmed: 34063671
Eur J Pharm Sci. 2017 Nov 15;109S:S59-S64
pubmed: 28552478
Stat Med. 2004 Oct 15;23(19):3053-76
pubmed: 15351960
Antimicrob Agents Chemother. 2013 Feb;57(2):950-8
pubmed: 23229480
Malar J. 2013 Jun 20;12:212
pubmed: 23782898
Clin Pharmacol Ther. 2019 Dec;106(6):1299-1309
pubmed: 31152555
Am J Trop Med Hyg. 2000 Mar;62(3):393-5
pubmed: 11037784
Am J Trop Med Hyg. 2007 Oct;77(4):779-89
pubmed: 17978087
Med J Aust. 1971 Feb 27;1(9):473-5
pubmed: 5552440
N Engl J Med. 2013 Oct 3;369(14):1381-2
pubmed: 24088113
Am J Trop Med Hyg. 1977 Nov;26(6 Pt 1):1116-28
pubmed: 413444
PLoS Med. 2017 Feb 7;14(2):e1002224
pubmed: 28170391
Clin Infect Dis. 2019 Apr 8;68(8):1311-1319
pubmed: 30952158
J Travel Med. 2005 May-Jun;12(3):133-5
pubmed: 15996441
Malar J. 2012 Aug 17;11:280
pubmed: 22900786
Trans R Soc Trop Med Hyg. 1994 Mar-Apr;88(2):218-9
pubmed: 8036680
Pathog Glob Health. 2020 Oct;114(7):388-392
pubmed: 32705964
PLoS Med. 2017 Aug 29;14(8):e1002379
pubmed: 28850568
J Antimicrob Chemother. 2018 Nov 1;73(11):3102-3113
pubmed: 30085149
J Health Popul Nutr. 2009 Feb;27(1):4-13
pubmed: 19248643
BMC Med. 2018 Jan 18;16(1):11
pubmed: 29347975
Trans R Soc Trop Med Hyg. 1994 Mar-Apr;88(2):220-2
pubmed: 8036681
Br J Clin Pharmacol. 2006 Jun;61(6):682-9
pubmed: 16722829
Antimicrob Agents Chemother. 2012 Apr;56(4):2146-9
pubmed: 22252800
Am J Trop Med Hyg. 2008 May;78(5):736-40
pubmed: 18458306
Lancet. 2019 Sep 14;394(10202):929-938
pubmed: 31327563
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28289025
N Engl J Med. 2019 Jan 17;380(3):229-241
pubmed: 30650326
Trans R Soc Trop Med Hyg. 1996 Mar-Apr;90(2):147-51
pubmed: 8761575
BMC Infect Dis. 2017 Apr 8;17(1):254
pubmed: 28390397
PLoS One. 2016 Aug 31;11(8):e0161311
pubmed: 27580098
Br J Clin Pharmacol. 2017 Apr;83(4):777-790
pubmed: 27767204
J Infect Dis. 2004 Oct 15;190(8):1456-63
pubmed: 15378438
J Am Med Assoc. 1952 Aug 23;149(17):1568-70
pubmed: 14945981
Adv Drug Deliv Rev. 2014 Jun;73:102-26
pubmed: 24189013
Am J Trop Med Hyg. 1953 Nov;2(6):949-57
pubmed: 13104803
BMC Med. 2015 Dec 11;13:294
pubmed: 26654101
Trop Med Int Health. 1999 May;4(5):383-9
pubmed: 10402975
Bull World Health Organ. 2015 Feb 1;93(2):74-83
pubmed: 25883400
J Am Med Assoc. 1952 Aug 23;149(17):1563-8
pubmed: 14945980
Am J Trop Med Hyg. 2010 Jun;82(6):1017-23
pubmed: 20519594
Malar J. 2018 Nov 15;17(1):427
pubmed: 30442143
PLoS Negl Trop Dis. 2018 Apr 20;12(4):e0006440
pubmed: 29677199
Drug Metab Pharmacokinet. 2009;24(1):25-36
pubmed: 19252334
Antimicrob Agents Chemother. 2013 Mar;57(3):1128-35
pubmed: 23254437
BMC Med. 2016 Oct 27;14(1):171
pubmed: 27784313
Malar J. 2012 Dec 14;11:417
pubmed: 23237576
Stat Med. 2006 Jan 30;25(2):247-65
pubmed: 16143968
J Natl Malar Soc. 1950 Dec;9(4):285-92
pubmed: 14804087
J Infect Dis. 2013 Dec 1;208(11):1906-13
pubmed: 23926329
J Clin Pharm Ther. 2019 Aug;44(4):508-524
pubmed: 30980418
Stat Med. 1997 Dec 30;16(24):2785-803
pubmed: 9483714
Antimicrob Agents Chemother. 2014;58(1):432-9
pubmed: 24189254